Neurophysiological Treatment Effects of Mesdopetam, Pimavanserin and Amantadine in a Rodent Model of Levodopa‐Induced Dyskinesia
European Journal of Neuroscience · 2025
DOI: 10.1111/ejn.70032 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Neuroscience, 2025. Verfasst von Abdolaziz Ronaghi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Translational Biology, Umeå University, Umeå, Sweden. Hauptthemen laut MEDLINE: Amantadine, Levodopa, Piperidines, Dyskinesia, Drug-Induced. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Konung Gustaf V:s och Drottning Victorias Foundation, Insamlingsstiftelserna, Umeå University.
Abstract (Originalsprache)
Levodopa provides effective symptomatic treatment for Parkinson's disease. However, nonmotor symptoms are often insufficiently relieved, and its long‐term use is complicated by motor fluctuations and dyskinesia. To clarify mechanisms of levodopa‐induced dyskinesia and pharmacological interventions aimed at reducing dyskinetic symptoms, we have here characterized the neurophysiological activity patterns in sensorimotor and cognitive‐limbic circuits in dyskinetic rats, comparing the effects of amantadine, pimavanserin, and the novel prospective antidyskinetic and antipsychotic treatment mesdopetam. Parallel recordings of local field potentials from 11 cortical and subcortical regions revealed suppression of narrowband gamma oscillations (NBGs) in sensorimotor structures by amantadine and mesdopetam in conjunction with alleviation of dyskinetic signs. Concomitant gamma oscillations in cognitive‐limbic circuits were not directly linked to dyskinesia and were not affected by antidyskinetic treatments to the same extent, although treatment‐induced reductions in functional coupling were observed in both sensorimotor and cognitive‐limbic circuits, in parallel. In a broad frequency spectrum (1–200 Hz), mesdopetam treatment displayed greater similarities to pimavanserin than to amantadine. These findings point to the reduction of NBGs as a valuable biomarker for the characterization of antidyskinetic treatment effects and provide systems‐level mechanistic insights into the antidyskinetic efficacy of mesdopetam, with potential additional benefits for the treatment of Parkinson's‐related psychosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Translational Biology, Umeå University, Umeå, Sweden.
- The Group for Integrative Neurophysiology and Neurotechnology, Department of Experimental Medical Science, Lund University, Lund, Sweden.
- Integrative Research Laboratories Sweden AB, Göteborg, Sweden.
ORCID-Profile: Luciano Censoni, Per Petersson
Förderung
- Konung Gustaf V:s och Drottning Victorias Foundation
- Insamlingsstiftelserna
- Umeå University
- The Kempe Foundation
- The Swedish Brain Foundation
- Vinnova
- Vetenskapsrådet
- Swedish Parkinson Foundation
Zitieren
APA
Ronaghi, A., Stan, T. L., Barrientos, S. A., Halje, P., Nasretdinov, A., Censoni, L., Sato, S. S., Malinina, E., Tedroff, J., Waters, N., & Petersson, P. (2025). Neurophysiological Treatment Effects of Mesdopetam, Pimavanserin and Amantadine in a Rodent Model of Levodopa‐Induced Dyskinesia. European Journal of Neuroscience. https://doi.org/10.1111/ejn.70032
Vancouver
Ronaghi A, Stan TL, Barrientos SA, Halje P, Nasretdinov A, Censoni L, et al. Neurophysiological Treatment Effects of Mesdopetam, Pimavanserin and Amantadine in a Rodent Model of Levodopa‐Induced Dyskinesia. European Journal of Neuroscience. 2025. doi:10.1111/ejn.70032
BibTeX
@article{Ronaghi2025,
author = {Ronaghi, Abdolaziz and Stan, Tiberiu Loredan and Barrientos, Sebastian A and Halje, Pär and Nasretdinov, Azat and Censoni, Luciano and Sato, Sebastian Sulis and Malinina, Evgenya and Tedroff, Joakim and Waters, Nicholas and Petersson, Per},
title = {Neurophysiological Treatment Effects of Mesdopetam, Pimavanserin and Amantadine in a Rodent Model of Levodopa‐Induced Dyskinesia},
journal = {European Journal of Neuroscience},
year = {2025},
doi = {10.1111/ejn.70032}
}
EUVIMED